Replies to post #1031 on InMed Pharmaceuticals Inc (INM)

[BigPennyHunter]

Stock is fine. It's trading at the low of its channel. 12 therapies in the pipeline. We are backed by the Canadian government. We're in excellent position here

[lesgetrich]

That article is very confusing and I don't think it really applies to Inmed's research. For one thing, it talks about THC and the unpleasant experience people have getting high which caused a lot of their test subject to drop out. It's also primarily targeted at people who smoke medical MJ to treat their glaucoma. It then shows a video of a Doctor who makes exactly the opposite point - i.e. that MJ is an effective treatment. If you go to the Glaucoma Research Foundation site, their statement, which this article is based on concludes the following...

Medical Marijuana

The only marijuana currently approved at the Federal level for medical use is Marinol, a synthetic form of tetrahydrocannabinol (THC), the most active component of marijuana. It was developed as an antiemetic (an agent that reduces nausea used in chemotherapy treatments), which can be taken orally in capsule form. The effects of Marinol on glaucoma are not impressive.

Medical Research Studies

(1) To date, no studies have shown that marijuana— or any of its approximately 400 chemical components—can safely and effectively lower intraocular pressure better than the variety of drugs currently on the market.

(2) Currently, there are no National Eye Institute studies in the United States concerning the use of marijuana to treat glaucoma.

(3) The Glaucoma Research Foundation will continue to monitor the research community for any new and well-designed studies regarding the use of marijuana to effectively treat glaucoma.

Inmed's research is primarily targeted at CBD compounds not THC which is what Marinol contains so it would be an apples to oranges comparison. Statement 1 is simply a statement of fact but doesn't point out that until recently, there haven't been any studies since it has been illegal to study MJ in the US and most foreign countries. Statement 2 is true because it is still illegal to study MJ in the US. Finally, in statement 3 they admit they'll keep watching the research.

Consequently, the only valuable takeaway from that study is the following...

The number of significant side effects generated by long-term oral use of marijuana or long-term inhalation of marijuana smoke make marijuana a poor choice in the treatment of glaucoma, a chronic disease requiring proven and effective treatment.

In other words don't give up your pills and start smoking weed instead. Inmed's research on the other hand uses their software platform to identify CBD compounds that can mimic the effects of certain effective drug treatments. They are a Canadian company and their clinical trials haven't been completed yet so the Glaucoma Research Foundation statement doesn't really apply to them.